Welcome to our dedicated page for Akari Therapeutics Plc news (Ticker: AKTX), a resource for investors and traders seeking the latest updates and insights on Akari Therapeutics Plc stock.
Akari Therapeutics plc (NASDAQ: AKTX) is an oncology biotechnology company whose news flow centers on the development of its PH1-based antibody–drug conjugates (ADCs). Company updates frequently highlight progress with its lead Trop2-targeting ADC, AKTX-101, and the broader PH1 spliceosome-modulating payload platform designed to disrupt RNA splicing in cancer cells and activate immune responses.
Investors following AKTX news can expect regular announcements on preclinical data, particularly in hard-to-treat solid tumors such as KRAS-mutant pancreatic ductal adenocarcinoma, urothelial (bladder) cancer, and gastric cancer. Akari’s releases often describe new efficacy and safety findings for AKTX-101, including comparisons with ADCs that use traditional payloads and exploratory work on synergy with checkpoint inhibitors.
Another recurring news theme is platform and pipeline development. Akari reports on the evolution of its ADC discovery platform, the advancement of additional candidates like AKTX-102 for GI and lung cancers, and scientific engagement through conference presentations and virtual investor segments such as its “CEO Corner” and “What This Means” features.
On the corporate side, Akari’s news includes financing transactions, such as registered direct offerings, private placements with warrants, and note exchanges that the company states are intended to fund research and development, working capital, and general corporate purposes. Updates on manufacturing partnerships, including GMP manufacturing of AKTX-101 with WuXi XDC, and disclosures related to Nasdaq listing requirements also appear in its news stream.
For readers tracking oncology innovation and early-stage ADC pipelines, the AKTX news page offers a focused view of how Akari is progressing its PH1 payload technology, preparing for potential clinical trials, and managing the capital and governance steps that support its development plans.
Akari Therapeutics (NASDAQ: AKTX) published a new CEO Corner on Dec 4, 2025 with a corporate update from CEO Abizer Gaslightwala.
The company described its ADC payload platform built around a novel PH1 payload that targets the spliceosome and reported a unique preclinical efficacy and safety profile. Akari named its lead candidate AKTX-101, a Trop2-directed ADC with a proprietary linker that delivers the PH1 payload to tumors. The company is initiating IND-enabling studies and plans to advance AKTX-101 into clinical trials in 4Q 2026.
Akari Therapeutics (Nasdaq: AKTX) announced on Nov 25, 2025 that a new CEO Corner segment is published on the company website. In the video, CEO Abizer Gaslightwala reviews Akari’s innovation in antibody drug conjugates (ADCs), highlights the company’s novel PH1 payload and its dual mechanism of action, and discusses the capabilities of Akari’s next‑generation ADC discovery platform. The segment reiterates the company’s mission to advance differentiated therapies for patients and is available for viewing on the company website.
Akari Therapeutics (Nasdaq: AKTX) announced on November 18, 2025 the appointment of Kameel D. Farag as Interim Chief Financial Officer; he joined Akari last month.
Mr. Farag brings >20 years of biotech finance and operations experience, including $170M+ capital raised across his career, securing $150M+ in financing at Aspen Neuroscience, supporting $1B+ revenue growth at Ionis, and leading international finance roles at Amgen. The company said his experience in corporate finance, M&A, and operational build-outs will support acceleration of Akari’s ADC platform and advancement of its lead asset toward the clinic.
Akari Therapeutics (NASDAQ: AKTX) presented preclinical immuno-oncology data for its novel spliceosome-targeting ADC payload, PH1, at the 40th Annual SITC Meeting on November 10, 2025. The data show PH1 drives cancer cell cytotoxicity and broad immune activation, including macrophage polarization, neutrophil increases, B-cell/IgM expansion, and gamma-delta T-cell expansion when combined with anti-PD1.
In an immune-competent HER2-positive colon tumor model, Trastuzumab-PH1 + anti-PD1 produced complete responses in 74% vs 42% (p<0.05) compared with Kadcyla + anti-PD1. Akari is advancing lead candidate AKTX-101 (Trop2-PH1) into IND-enabling studies and will host a live webcast on Nov 18, 2025 at 11:00 AM ET.
Akari Therapeutics (Nasdaq: AKTX) announced its SITC 40 abstract and presentations on November 7 and 9, 2025 describing preclinical immune mechanism data for its novel ADC payload PH1.
The company reports that a Trastuzumab–PH1 ADC produced higher rates of complete colon-tumor regressions versus a comparator microtubule-inhibitor ADC when combined with an anti‑PD‑1 checkpoint inhibitor. The PH1 combination is attributed to neoantigen-driven immune activation, antigen-presenting cell, B-cell and T-cell engagement, and expansion of tumor‑killing gamma‑delta T cells. Poster and oral presentation details and times are provided for the SITC Annual Meeting.
Akari Therapeutics (Nasdaq: AKTX) announced on October 30, 2025 the formation of a Scientific Advisory Board and the inaugural appointment of Dr. Sara A. Hurvitz, MD, FACP.
Dr. Hurvitz is described as an international oncology expert with extensive clinical trial leadership and specific experience in antibody drug conjugates (ADCs) and breast cancer therapies. She currently holds leadership roles at the University of Washington School of Medicine and Fred Hutchinson Cancer Center. The company noted its ADC pipeline includes AKTX-101 (Trop2 ADC with PH1 payload) and future programs such as AKTX-102.
Akari Therapeutics (Nasdaq: AKTX) launched a new CEO Corner platform on Oct 22, 2025 to deliver expanded perspective on press releases, corporate developments and pipeline progress.
The video platform features Abizer Gaslightwala, President and CEO, and allows interested parties to ask questions and submit topics for future videos. The CEO Corner is accessible on the company website.
Akari Therapeutics (Nasdaq: AKTX) announced a registered direct offering of 3,125,000 ADS at $0.80 per ADS, representing gross proceeds of approximately $2.5 million. In a concurrent private placement the company will issue unregistered Series E and Series F warrants, each to purchase up to 3,125,000 ADS at an exercise price of $0.98. Series E warrants: exercisable on shareholder approval and five-year term; Series F warrants: exercisable on shareholder approval and 30-month term. The offering is expected to close on or about October 16, 2025. Net proceeds are intended for working capital, general corporate purposes, and continued R&D focused on the novel ADC payload.
The ADSs are offered under an effective Form S-3 shelf registration (File No. 333-289056) declared effective July 31, 2025; the warrants and underlying ADSs are unregistered.
Akari Therapeutics (Nasdaq: AKTX) filed two provisional patent applications with the USPTO on Oct 9, 2025 to broaden intellectual property around its novel spliceosome‑modulating payload PH1. One filing claims PH1's immuno‑oncology mode of action via spliceosome modulation; the second claims combination therapies pairing PH1 ADCs with checkpoint inhibitors, citing preclinical synergy. These filings build on a late‑September provisional covering alternative splicing targeting and are intended to protect disclosures planned for an oral presentation at SITC on Nov 9, 2025. The release highlights AKTX‑101 (Trop2‑PH1 ADC) and future programs including AKTX‑102 as part of the expanding PH1 ADC pipeline.
Akari Therapeutics (Nasdaq: AKTX) announced an abstract accepted for an oral presentation at the 40th Annual SITC Meeting on Nov 5-9, 2025 in National Harbor, MD. The oral talk, titled "A Novel Splicing-Targeted ADC Payload Drives Immune Activation, Synergy with Checkpoint Inhibitors, and Enhanced Therapeutic Potential beyond Cytotoxicity," will be presented by Satyajit Mitra, Ph.D. on Sunday, Nov 9, 2025 at 11:05 AM ET in the Potomac Ballroom. A related poster will be presented on Friday, Nov 7, 2025 in Prince George ABC Exhibit Halls. For more details see sitcancer.org.
FAQ
What is the current stock price of Akari Therapeutics Plc (AKTX)?
What is the market cap of Akari Therapeutics Plc (AKTX)?
